The North America Biosimulation Market is expected to witness market growth of 16.1% CAGR during the forecast period (2024-2031).
The US market dominated the North America Biosimulation Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $3.57 billion by 2031. The Canada market is experiencing a CAGR of 18.7% during 2024-2031. Additionally, the Mexico market is expected to exhibit a CAGR of 17.7% during 2024-2031.
This market is at the forefront of a transformative wave in the healthcare and pharmaceutical industries. This cutting-edge field combines computational science with biology to simulate complex biological systems, offering unprecedented insights into drug development, disease progression, and therapeutic responses.
At its core, they involves creating virtual models of biological systems, enabling scientists to study the intricate processes of the human body without the need for extensive laboratory experiments. This capability has revolutionized pharmaceutical research by allowing researchers to simulate how drugs interact with biological pathways, predict outcomes, and optimize dosing regimens.
Due to growing healthcare expenditures and a changing private healthcare industry, Mexico is becoming a major player in the North American market. The country’s increasing disease burden, such as the projected rise in diabetes cases from 12.8 million in 2019 to 22.3 million by 2045, underscores the critical need for advanced healthcare solutions. These platforms play a vital role in helping healthcare providers optimize drug therapies and manage chronic diseases more effectively. These tools and lifestyle disease management applications are crucial for addressing this growing health crisis. Therefore, with increasing investments in personalized medicine, biologics, and rare disease therapies, North America remains a key driver of growth in the global biosimulation landscape.
The US market dominated the North America Biosimulation Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $3.57 billion by 2031. The Canada market is experiencing a CAGR of 18.7% during 2024-2031. Additionally, the Mexico market is expected to exhibit a CAGR of 17.7% during 2024-2031.
This market is at the forefront of a transformative wave in the healthcare and pharmaceutical industries. This cutting-edge field combines computational science with biology to simulate complex biological systems, offering unprecedented insights into drug development, disease progression, and therapeutic responses.
At its core, they involves creating virtual models of biological systems, enabling scientists to study the intricate processes of the human body without the need for extensive laboratory experiments. This capability has revolutionized pharmaceutical research by allowing researchers to simulate how drugs interact with biological pathways, predict outcomes, and optimize dosing regimens.
Due to growing healthcare expenditures and a changing private healthcare industry, Mexico is becoming a major player in the North American market. The country’s increasing disease burden, such as the projected rise in diabetes cases from 12.8 million in 2019 to 22.3 million by 2045, underscores the critical need for advanced healthcare solutions. These platforms play a vital role in helping healthcare providers optimize drug therapies and manage chronic diseases more effectively. These tools and lifestyle disease management applications are crucial for addressing this growing health crisis. Therefore, with increasing investments in personalized medicine, biologics, and rare disease therapies, North America remains a key driver of growth in the global biosimulation landscape.
List of Key Companies Profiled
- Certara, Inc.
- Dassault Systemes SE
- Advanced Chemistry Development, Inc.
- Genedata AG (Danaher Corporation)
- Instem Group of Companies
- Chemical Computing Group ULC
- Simulations Plus, Inc.
- Schrodinger, Inc.
- PPD, Inc. (Thermo Fisher Scientific, Inc.)
- Physiomics Plc
Market Report Segmentation
By Product- Software
- Molecular Modeling & Simulation Software
- Clinical Trial Design Software
- PK/PD Modeling and Simulation Software
- Pbpk Modeling and Simulation Software
- Toxicity Prediction Software
- Other Software Type
- Services
- Contract Services
- Consulting
- Other Services Type
- License-based Model
- Subscription-based Model
- Service-based Model
- Pay Per Use Model
- Life Sciences Companies
- Academic Research Institutions
- Other End Use
- Drug Discovery & Development
- Disease Modeling
- Other Application
- Cloud-based
- On-premises
- Hybrid Model
- Oncology
- Cardiovascular Disease
- Infectious Disease
- Neurological Disorders
- Other Therapeutic Area
- US
- Canada
- Mexico
- Rest of North America
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. North America Biosimulation Market by Product
Chapter 6. North America Biosimulation Market by Pricing Model
Chapter 7. North America Biosimulation Market by End Use
Chapter 8. North America Biosimulation Market by Application
Chapter 9. North America Biosimulation Market by Deployment Model
Chapter 10. North America Biosimulation Market by Therapeutic Area
Chapter 11. North America Biosimulation Market by Country
Chapter 12. Company Profiles
Companies Mentioned
- Certara, Inc.
- Dassault Systemes SE
- Advanced Chemistry Development, Inc.
- Genedata AG (Danaher Corporation)
- Instem Group of Companies
- Chemical Computing Group ULC
- Simulations Plus, Inc.
- Schrodinger, Inc.
- PPD, Inc. (Thermo Fisher Scientific, Inc.)
- Physiomics Plc
Methodology
LOADING...
